{
    "id": 25467,
    "fullName": "ERBB2 V773L",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) V773L lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V773L confers a gain of function to the Erbb2 (Her2) protein as demonstrated by increased tyrosine kinase activity and phosphorylation compared to wild-type, and abnormal cellular morphology in culture (PMID: 27697991).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 6720,
                    "pubMedId": 27697991,
                    "title": "Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27697991"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "V773L",
    "createDate": "10/10/2016",
    "updateDate": "10/10/2016",
    "referenceTranscriptCoordinates": {
        "id": 170792,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39724735G>C",
        "cDna": "c.2317G>C",
        "protein": "p.V773L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8753,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991).",
            "molecularProfile": {
                "id": 26428,
                "profileName": "ERBB2 V773L"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6720,
                    "pubMedId": 27697991,
                    "title": "Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27697991"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8754,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Nerlynx (nerlatinib) in culture, resulting in decreased colony formation (PMID: 27697991).",
            "molecularProfile": {
                "id": 26428,
                "profileName": "ERBB2 V773L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6720,
                    "pubMedId": 27697991,
                    "title": "Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27697991"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8752,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991).",
            "molecularProfile": {
                "id": 26428,
                "profileName": "ERBB2 V773L"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6720,
                    "pubMedId": 27697991,
                    "title": "Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27697991"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26428,
            "profileName": "ERBB2 V773L",
            "profileTreatmentApproaches": [
                {
                    "id": 10645,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB2 V773L"
                },
                {
                    "id": 10644,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB2 V773L"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170793,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39724735G>C",
            "cDna": "c.2317G>C",
            "protein": "p.V773L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170792,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39724735G>C",
            "cDna": "c.2317G>C",
            "protein": "p.V773L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}